Management will host a live webcast at 3:30 p.m. CT to walk stakeholders through the latest quarterly figures. Those interested in following the discussion can access the broadcast via the company’s investor relations portal. Following the presentation, a recorded version of the call will remain available on the Caris Life Sciences website for those unable to attend the live session.

Headquartered in Irving, the company continues to focus on its core business of molecular profiling and precision medicine. By integrating whole genome and transcriptome sequencing with proprietary machine learning tools, Caris aims to bridge the gap between complex disease data and clinical application. The upcoming report serves as a key indicator of the firm’s ongoing efforts to scale these diagnostic solutions across both U.S. and international markets.